Browse Category

NASDAQ:NAMS News 11 October 2025 - 5 January 2026

NewAmsterdam Pharma stock slides on insider sale notices — what investors watch next for NAMS

NewAmsterdam Pharma stock slides on insider sale notices — what investors watch next for NAMS

New York, Jan 5, 2026, 15:21 EST — Regular session Shares of NewAmsterdam Pharma Company N.V. fell about 5% to $33.42 in afternoon trading on Monday. The Nasdaq-listed stock hit an intraday low of $32.68 after opening at $35.15. The move followed two Form 144 filings that signaled planned sales by company affiliates. In smaller biotech names, even routine insider activity can sway short-term sentiment when liquidity is thinner. Form 144 is an SEC notice filed before certain holders sell stock under Rule 144, which governs resales of restricted or “control” shares. The filing does not confirm a sale, but
NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know

NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know

Company Overview: History & Mission NewAmsterdam Pharma Company N.V. is a Netherlands-based biotech (with U.S. operations in Miami) on a mission to “change the landscape of lipid-lowering treatment” for cardiovascular disease Newamsterdampharma. Founded in early 2020, the company sprang from the vision of Prof. John J.P. Kastelein – a world-renowned expert in lipid disorders – and venture capital firm Forbion Newamsterdampharma. They acquired the rights to obicetrapib, a once-abandoned CETP inhibitor, from an Amgen subsidiary in 2020 Newamsterdampharma. Soon after, Dr. Michael Davidson (a leading preventive cardiologist) joined as co-founder and CEO, bringing deep clinical expertise to the leadership team

Stock Market Today

iFAST share price drops 3% as markets shut; earnings next week in focus

iFAST share price drops 3% as markets shut; earnings next week in focus

7 February 2026
iFAST shares fell 3.2% to S$9.64 in heavy trading Friday, closing near the day’s low as investors awaited FY2025 results due Feb. 12. The stock is about 13% below its 52-week high. iFAST recently agreed to buy a 30% stake in Financial Alliance for S$19.6 million, pending regulatory approval. Assets under administration stood at S$30.62 billion as of Sept. 30.
Sembcorp Industries share price: what to watch after Friday dip as Feb 25 results near

Sembcorp Industries share price: what to watch after Friday dip as Feb 25 results near

7 February 2026
Sembcorp shares closed at S$6.05 on Friday, down 0.33%, as Singapore’s STI dropped 0.8%. Shareholders approved the A$6.5 billion Alinta Energy takeover on Jan 30, but the deal still faces regulatory and closing conditions. Sembcorp will release FY2025 results on Feb 25 before market open. Trading volume reached about 4.3 million shares.
Hongkong Land share price drops 4% despite fresh buyback — what investors watch next

Hongkong Land share price drops 4% despite fresh buyback — what investors watch next

7 February 2026
Hongkong Land shares fell 4.2% to US$8.18 in Singapore on Friday after the company disclosed a buyback of 170,000 shares at US$8.5252 each on Feb. 5, with plans to cancel them. The drop followed a volatile week marked by a new Singapore real estate fund launch and an expanded buyback programme. Investors are watching for the group’s annual results on March 5.
Go toTop